Nurse Practitioner Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Dorothy Terrell

Registered Nurse, Women's Health Care, Ambulatory Columbia, SC Nurse Practitioner

NPI 1891912937 CMS profile 10714421

2000 Hampton St, Columbia, SC 29204

Open in the dashboard

General payments

$668

36 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Dorothy Terrell of Columbia, SC is reported in the CMS Open Payments database as having received $668 across 36 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $33 2
2022 General $227 12
2021 General $408 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dorothy Terrell
  • Registered Nurse, Women's Health Care, Ambulatory median
  • Middle half of Registered Nurse, Women's Health Care, Ambulatory
  • National median

In program year 2025, general payments to Dorothy Terrell were reported at $0. Among 44 Registered Nurse, Women's Health Care, Ambulatory profiles paid that year, the median was $102 and the middle half received between $30 and $276.

Show as a table
Year Dorothy Terrell Registered Nurse, Women's Health Care, Ambulatory median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $408 $156 $106–$276 $132
2022 $227 $155 $46–$289 $149
2023 $33 $117 $33–$282 $160
2024 $0 $69 $30–$246 $164
2025 $0 $102 $30–$276 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. AbbVie, Inc. $360 20 payments
  2. TherapeuticsMD, Inc. $60 3 payments
  3. Mylan Pharmaceuticals Inc. $57 3 payments
  4. Exeltis, USA Inc. $55 3 payments
  5. SCYNEXIS, Inc. $35 1 payment
  6. Myovant Sciences Inc. $35 2 payments
  7. Agile Therapeutics, Inc. $27 2 payments
  8. Evofem Biosciences, Inc. $20 1 payment
  9. CooperSurgical, Inc. $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $668 36 payments
Products named General payments · program years 2021–2023
  1. LO LOESTRIN FE $239 13 payments
  2. LILETTA $121 7 payments
  3. ANNOVERA $60 3 payments
  4. SLYND $55 3 payments
  5. Xulane Contraceptives, Transdermal $40 2 payments
  6. MYFEMBREE $35 2 payments
  7. Twirla $27 2 payments
  8. Phexxi $20 1 payment
  9. Paragard $18 1 payment
  10. Xulane Contraceptives, Transdermal $17 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

36 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Registered Nurse, Women's Health Care, Ambulatory in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record